Ingevity Co. (NYSE:NGVT) Stock Holdings Lifted by Barclays PLC

Barclays PLC lifted its position in Ingevity Co. (NYSE:NGVT) by 245.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 66,761 shares of the company’s stock after acquiring an additional 47,429 shares during the quarter. Barclays PLC owned approximately 0.18% of Ingevity worth $2,603,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the company. Amalgamated Bank raised its stake in Ingevity by 2.4% during the 3rd quarter. Amalgamated Bank now owns 10,667 shares of the company’s stock valued at $416,000 after purchasing an additional 246 shares during the period. First Horizon Advisors Inc. raised its position in Ingevity by 45.9% during the third quarter. First Horizon Advisors Inc. now owns 862 shares of the company’s stock valued at $34,000 after buying an additional 271 shares during the period. Louisiana State Employees Retirement System lifted its stake in Ingevity by 1.8% in the 2nd quarter. Louisiana State Employees Retirement System now owns 17,000 shares of the company’s stock worth $743,000 after acquiring an additional 300 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its position in Ingevity by 1.2% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 25,739 shares of the company’s stock worth $1,004,000 after acquiring an additional 313 shares during the period. Finally, KBC Group NV boosted its position in Ingevity by 50.8% during the 3rd quarter. KBC Group NV now owns 1,574 shares of the company’s stock worth $61,000 after acquiring an additional 530 shares during the period. Hedge funds and other institutional investors own 91.59% of the company’s stock.

Wall Street Analyst Weigh In

Separately, BMO Capital Markets increased their price target on shares of Ingevity from $40.00 to $47.00 and gave the stock a “market perform” rating in a research report on Thursday, October 31st. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Ingevity has a consensus rating of “Moderate Buy” and an average price target of $52.17.

Ingevity Stock Performance

Shares of NGVT stock opened at $41.46 on Wednesday. Ingevity Co. has a fifty-two week low of $30.90 and a fifty-two week high of $56.29. The stock’s 50-day moving average is $43.11 and its two-hundred day moving average is $41.24. The company has a debt-to-equity ratio of 6.52, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market cap of $1.51 billion, a P/E ratio of -2.67 and a beta of 1.62.

Ingevity (NYSE:NGVT) last released its quarterly earnings data on Tuesday, October 29th. The company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.50. The firm had revenue of $376.90 million for the quarter, compared to the consensus estimate of $376.95 million. Ingevity had a positive return on equity of 24.46% and a negative net margin of 38.11%. The firm’s revenue was down 15.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.21 earnings per share. Analysts predict that Ingevity Co. will post 2.55 earnings per share for the current fiscal year.

About Ingevity

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.